The pharmacokinetics of pioglitazone in patients with impaired renal function
Open accessThe DOI matches its Crossref record.
Abstract
Aims To evaluate the effect of renal impairment on the pharmacokinetics and safety of pioglitazone and its metabolites M‐III and M‐IV with impaired renal function and normal renal function. Methods In a phase‐I, open‐label, parallel‐group study, six healthy subjects with normal renal function (creatinine clearance> 80 ml min−1), nine patients with moderate renal impairment (creatinine clearance 30–60 ml min−1) and 12 patients with severe renal impairment (creatinine clearance < 30 ml min−1) received single and multiple oral doses of pioglitazone 45 mg. The serum pharmacokinetic profiles of pioglitazone and its metabolites M‐III and M‐IV were assessed for the first and last dose administered (day 1 and day 12, respectively). Results Pharmacokinetic data revealed no significant accumulation of pioglitazone or its metabolites M‐III and M‐IV in patients with renal impairment. There was no significant difference in the pharmacokinetic profile of pioglitazone in subjects with normal and with moderately impaired renal function. After single oral doses, mean area under the concentration‐time curve (AUC) values were decreased in patients with severe renal impairment compared with healthy subjects with normal renal function for pioglitazone (13 476 vs 17 387, P = 0.371; −23%; confidence interval (CI) −57, 38), M‐III metabolite (13 394 vs 15 071, P = 0.841; −11%; CI −74, 194) and M‐IV metabolite (27 991 vs 49 856, P = 0.006; −44%; CI −62, −17). After repeated oral doses of pioglitazone, mean AUC values (µg.h l−1) were decreased in patients with severe renal impairment compared with healthy subjects with normal renal function for pioglitazone (8744 vs 14,565, P = 0.004; −40%; CI −57, −16), M‐III (3991 vs 7,289, P = 0.0009; −45%; CI −60, −25) and M‐IV (21 080 vs 25 706, P = 0.181; −18%; CI 39, 10). The tolerability and safety profile of pioglitazone was comparable between groups. Conclusions Pioglitazone was well tolerated in patients with varying degrees of renal impairment. Although mean serum concentrations of pioglitazone and its metabolites are increased in patients with severe renal impairment, adjustment of starting and maintenance doses in these patients is probably unwarranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
“Thiazolidinediones have been used successfully in patients with liver andkidney transplants, but side effects include fluid retention, heart failure, and osteopenia (98,99).”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Metadata
- Authors
- Budde, K., Neumayer, H., Fritsche, L., Sulowicz, W., Stompôr, T., & Eckland, D.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-04
- Volume
- 55
- Issue
- 4
- Pages
- 368-374
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1596678070
- Cited by
- 143
- References
- 0
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pharmacokinetics of pioglitazone in patients with impaired renal function. https://app.cochat.ai/papers/10.1046/j.1365-2125.2003.01785.x
- The paper
- Budde, K., Neumayer, H., Fritsche, L., Sulowicz, W., Stompôr, T., & Eckland, D. (2003). The pharmacokinetics of pioglitazone in patients with impaired renal function. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2003.01785.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.